This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. BFRG, TXMD, PMN, LPTX, GELS, ALLR, GOVX, CING, COCP, and FLGCShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Bullfrog AI (BFRG), TherapeuticsMD (TXMD), ProMIS Neurosciences (PMN), Leap Therapeutics (LPTX), Gelteq (GELS), Allarity Therapeutics (ALLR), GeoVax Labs (GOVX), Cingulate (CING), Cocrystal Pharma (COCP), and Flora Growth (FLGC). These companies are all part of the "medical" sector. Novus Therapeutics vs. Bullfrog AI TherapeuticsMD ProMIS Neurosciences Leap Therapeutics Gelteq Allarity Therapeutics GeoVax Labs Cingulate Cocrystal Pharma Flora Growth Bullfrog AI (NASDAQ:BFRG) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk. Does the media favor BFRG or NVUS? In the previous week, Bullfrog AI's average media sentiment score of 0.00 equaled Novus Therapeutics'average media sentiment score. Company Overall Sentiment Bullfrog AI Neutral Novus Therapeutics Neutral Is BFRG or NVUS more profitable? Novus Therapeutics' return on equity of -133.49% beat Bullfrog AI's return on equity.Company Net Margins Return on Equity Return on Assets Bullfrog AIN/A -141.39% -124.63% Novus Therapeutics N/A -133.49%-30.52% Which has stronger valuation & earnings, BFRG or NVUS? Bullfrog AI has higher revenue and earnings than Novus Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBullfrog AI$60K290.30-$5.36M-$0.81-2.28Novus TherapeuticsN/AN/A-$16.01M-$21.58-0.14 Which has more volatility & risk, BFRG or NVUS? Bullfrog AI has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Do institutionals & insiders believe in BFRG or NVUS? 1.0% of Bullfrog AI shares are owned by institutional investors. 33.9% of Bullfrog AI shares are owned by company insiders. Comparatively, 2.2% of Novus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in BFRG or NVUS? Novus Therapeutics received 252 more outperform votes than Bullfrog AI when rated by MarketBeat users. Likewise, 66.84% of users gave Novus Therapeutics an outperform vote while only 0.00% of users gave Bullfrog AI an outperform vote. CompanyUnderperformOutperformBullfrog AIOutperform VotesNo VotesUnderperform Votes1100.00% Novus TherapeuticsOutperform Votes25266.84% Underperform Votes12533.16% SummaryNovus Therapeutics beats Bullfrog AI on 6 of the 11 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.38M$6.46B$5.33B$8.31BDividend YieldN/A2.63%5.27%4.10%P/E Ratio-0.148.3626.7119.58Price / SalesN/A258.95395.62135.28Price / CashN/A65.8538.3234.62Price / Book0.236.416.764.50Net Income-$16.01M$143.73M$3.23B$248.40M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$3.05+1.0%N/A+1.0%$4.38MN/A-0.147High Trading VolumeBFRGBullfrog AI0.4629 of 5 stars$1.83+4.9%N/A-37.7%$17.18M$60,000.00-2.154Positive NewsGap UpTXMDTherapeuticsMD0.8925 of 5 stars$1.48-0.3%N/A-31.3%$17.07M$1.76M0.00420News CoverageAnalyst ForecastPMNProMIS Neurosciences1.5941 of 5 stars$0.51+2.8%$4.50+775.5%-68.8%$16.80MN/A-5.145Gap UpLPTXLeap Therapeutics2.4183 of 5 stars$0.40-2.8%$4.92+1,120.0%-85.2%$16.78MN/A-0.2140Gap DownGELSGelteqN/A$1.77-5.9%N/AN/A$16.71MN/A0.00N/AGap DownALLRAllarity Therapeutics0.1344 of 5 stars$1.09+1.9%N/A-94.3%$16.59MN/A0.0010Analyst UpgradeGap DownGOVXGeoVax Labs2.7928 of 5 stars$1.05+2.9%$11.10+957.1%-40.2%$15.95M$5.59M-0.2910Positive NewsCINGCingulate2.1143 of 5 stars$3.71-2.6%$25.75+594.1%+343.6%$15.75MN/A-0.4420Analyst RevisionCOCPCocrystal Pharma3.2203 of 5 stars$1.52+7.4%$7.00+362.0%-29.5%$15.41MN/A-0.8210News CoveragePositive NewsAnalyst RevisionFLGCFlora Growth2.4836 of 5 stars$0.66-0.6%$4.00+505.1%-41.5%$14.95M$53.26M-0.68280 Related Companies and Tools Related Companies BFRG Alternatives TXMD Alternatives PMN Alternatives LPTX Alternatives GELS Alternatives ALLR Alternatives GOVX Alternatives CING Alternatives COCP Alternatives FLGC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVUS Stock Free NVUS Stock Alerts